{
    "clinical_study": {
        "@rank": "134332", 
        "arm_group": [
            {
                "arm_group_label": "Aflibercept with Laser", 
                "arm_group_type": "Active Comparator", 
                "description": "A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks"
            }, 
            {
                "arm_group_label": "Aflibercept", 
                "arm_group_type": "Experimental", 
                "description": "2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This 52 week study will assess the use of intravitreal aflibercept injections in patients\n      with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation.\n\n      The investigators hypothesize that the neovascularization of the iris and angle present in\n      neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept\n      injection alone and result in increased comfort and preservation of visual field as compared\n      to current standard of care utilizing pan-retinal photocoagulation. The advantages to\n      intravitreal aflibercept injection use could include resolution of NVI/NVA leading to\n      quicker pain relief and quicker lowering of IOP."
        }, 
        "brief_title": "Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neovascular Glaucoma", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Neovascular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a diagnosis of neovascular glaucoma  (Stage I-II)\n\n          -  Individuals who are ages 21-90 years old; male or female of any race\n\n          -  Presence of neovascularization of the iris and/or angle\n\n          -  At least 90 degrees of \"unzipped\" anterior chamber angle as noted by gonioscopy.  (a\n             \"zipped angle is the term used for a drainage angle that is slowly closing due to\n             scar tissue from the neovascularization process)\n\n          -  Visual acuity of light perception or better in the study eye\n\n          -  Willing and able to comply with clinic visits and study-related procedures\n\n          -  Provide signed informed consent\n\n        Exclusion Criteria:\n\n          -  Use of intravitreal anti-VEGF agents in the study eye in the past 3 months.\n\n          -  Full PRP in the study eye\n\n          -  Prior vitrectomy in the study eye\n\n          -  Prior trabeculectomy or other filtration surgery in the study eye\n\n          -  Active ocular or periocular infection in the study eye\n\n          -  Ocular conditions (Cataract or vitreous hemorrhage) that might require surgery in\n             next 12 months\n\n          -  Allergy to fluorescein dye\n\n          -  Any past use of systemic anti-VEGF medication\n\n          -  Myocardial infarction within 6 months prior to study enrollment\n\n          -  Stroke within 6 months prior to study enrollment\n\n          -  Pregnant or breast-feeding women\n\n          -  Sexually active men or women of childbearing potential who are unwilling to practice\n             adequate contraception during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711879", 
            "org_study_id": "12-1526"
        }, 
        "intervention": {
            "arm_group_label": [
                "Aflibercept with Laser", 
                "Aflibercept"
            ], 
            "description": "Details covered in arm description", 
            "intervention_name": "Aflibercept", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aurora", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80045"
                }, 
                "name": "Rocky Mountain Lions Eye Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Malik Y Kahook, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the incidence and severity of adverse events", 
            "measure": "Incidence and Severity of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711879"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Compare between Groups A and B\nRate and extent of resolution of neovascularization in patients with NVG Stages 1 & 2\nMean change in intraocular pressure(IOP) as measured by Goldmann applanation tonometry\nProportion of patients losing > 5 letters on visual acuity\nProportion of patients gaining \u2265 5 letters on visual acuity\nMean change in visual acuity\nVisual field as measured by HVF 24-2 SITA Standards\nOptical Coherence Tomography(OCT) outcomes (average retinal nerve fiber layer(RNFL) and central macular thickness)\nNeed for additional IOP lowering medications\nNeed for surgical intervention in both arms during the follow-up period", 
            "measure": "Comparison Between Groups", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}